These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23403120)

  • 1. Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.
    Zhang J; Mulvenon A; Makarov E; Wagoner J; Knibbe J; Kim JO; Osna N; Bronich TK; Poluektova LY
    Biomaterials; 2013 May; 34(15):3846-57. PubMed ID: 23403120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics.
    Zhang J; Garrison JC; Poluektova LY; Bronich TK; Osna NA
    Biomaterials; 2015 Nov; 70():37-47. PubMed ID: 26298393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
    Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
    New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity of virocidal peptide derived from NS5A against two different HCV genotypes: an in vitro study.
    El-Shenawy R; Tabll A; Bader El Din NG; El Abd Y; Mashaly M; Abdel Malak CA; Dawood R; El-Awady M
    J Immunoassay Immunochem; 2015; 36(1):63-79. PubMed ID: 24606010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.
    Gallay PA; Bobardt MD; Chatterji U; Trepanier DJ; Ure D; Ordonez C; Foster R
    PLoS One; 2015; 10(8):e0134707. PubMed ID: 26263487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.
    Shafran SD
    Clin Infect Dis; 2015 Oct; 61(7):1127-34. PubMed ID: 26060286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.
    Cheng G; Montero A; Gastaminza P; Whitten-Bauer C; Wieland SF; Isogawa M; Fredericksen B; Selvarajah S; Gallay PA; Ghadiri MR; Chisari FV
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3088-93. PubMed ID: 18287023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection.
    Masgala A; Bonovas S; Nikolopoulos GK
    Mini Rev Med Chem; 2012 Aug; 12(9):890-904. PubMed ID: 22530578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals.
    Zeremski M; Martinez AD; Talal AH
    Clin Infect Dis; 2014 Mar; 58(6):880-2. PubMed ID: 24336913
    [No Abstract]   [Full Text] [Related]  

  • 11. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.
    Sherman KE; Guedj J; Shata MT; Blackard JT; Rouster SD; Castro M; Feinberg J; Sterling RK; Goodman Z; Aronow BJ; Perelson AS
    Sci Transl Med; 2014 Jul; 6(246):246ra98. PubMed ID: 25101888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV co-infected patients.
    Bader T
    J Viral Hepat; 2010 Mar; 17(3):227. PubMed ID: 19758277
    [No Abstract]   [Full Text] [Related]  

  • 14. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating HCV in HIV 2013: on the cusp of change.
    Martel-Laferrière V; Dieterich DT
    Liver Int; 2014 Feb; 34 Suppl 1():53-9. PubMed ID: 24373079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic.
    Kieran J; Dillon A; Farrell G; Jackson A; Norris S; Mulcahy F; Bergin C
    Int J STD AIDS; 2011 Oct; 22(10):571-6. PubMed ID: 21998177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
    Chary A; Winters MA; Eisen R; Knight TH; Asmuth DM; Holodniy M
    J Med Virol; 2012 Mar; 84(3):431-7. PubMed ID: 22246828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.
    Papasavvas E; Azzoni L; Yin X; Liu Q; Joseph J; Mackiewicz A; Ross B; Lynn KM; Jacobson JM; Mounzer K; Kostman JR; Montaner LJ
    J Viral Hepat; 2017 Oct; 24(10):865-876. PubMed ID: 28419653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.
    Clement ME; Collins LF; Wilder JM; Mugavero M; Barker T; Naggie S
    Infect Dis Clin North Am; 2018 Jun; 32(2):407-423. PubMed ID: 29778263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.